# Bromocriptine

## Volbro 2.5mg

| TAH Drug Code      | [OPARL](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=OPARL)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|:-------------------|:---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Galactorrhea &/or prolactin-dependent amenorrhea, female infertility, Suppression of lactation, Pre-menstrual syndrome, Male hypogonadism, Acromegaly, Parkinson's disease.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Dosing             | Galactorrhea/hyperprolactinemia related amenorrhea or female infertility: 2.5 mg BID-TID. If the effect is not significant, can slowly increased to 5mg BID-TID. Inhibition of lactation: 5 mg BID for 14 days to maximum of 21 days. Premenstrual syndrome: 2.5 mg once daily from day 14 of the cycle, increment of 2.5mg every day to 2.5 mg twice daily, continue use until menstruation. Prolactin induced male hypogonadism: 10-20 mg daily. Prolactinoma: 2.5 mg BID-TID initially, slowly increase dose until optimal therapeutic response achieved. Acromegaly: 5mg daily and slowly increased to 20-40mg/day in 4 divided doses. Parkinsonism: start from 1.25 mg QD-BID, increased by 2.5 mg daily in 3-day or longer intervals as tolerated. Usual dose: 20-40mg/day.                                                                                                                                                                                                                                                                                                                              |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Contraindications  | Hypersensitivity to bromocriptine or ergot alkaloids, uncontrolled hypertension during pregnancy, post-partum or puerperal period.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Adverse Effects    | Slight nausea, dizziness, fatigue, vomiting, orthostatic hypotension, constipation, drowsiness. Cardiovascular: Hypotension (type 2 diabetes, 2.2% ) Gastrointestinal: Constipation (acromegaly, 14%; hyperprolactinemic indications, 3%; type 2 diabetes, 5.8% to 11.3% ), Diarrhea (hyperprolactinemic indications, 3%; type 2 diabetes, 8.1% to 8.8% ), Indigestion (acromegaly, 4%; type 2 diabetes, 7.5% ), Nausea (acromegaly, 18%; hyperprolactinemic indications, 49%; type 2 diabetes, 25.4% to 32.5% ), Vomiting (acromegaly, 2%; hyperprolactinemic indications, 5%; type 2 diabetes, 5.3% to 8.1% ) Neurologic: Asthenia (type 2 diabetes, 12.5% to 18.9% ), Dizziness (hyperprolactinemic indications, 17%; type 2 diabetes, 11.9% to 14.8% ), Headache (hyperprolactinemic indications, 19%; type 2 diabetes, 11.4% to 16.8% ), Somnolence ( 3% to 6.6% ) Ophthalmic: Amblyopia (type 2 diabetes, 5.3% to 7.5% ) Respiratory: Rhinitis (type 2 diabetes 10.7% to 13.8% ), Sinusitis (type 2 diabetes, 7.4% to 10% ) Other: Fatigue (hyperprolactinemia indications, 7%; type 2 diabetes, 13.9% ) |
| Pregnancy          | Compatible                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Lactation          | Contraindicated                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |

